NEUROPACE INC (NPCE) Stock Price & Overview
NASDAQ:NPCE • US6412881053
Current stock price
The current stock price of NPCE is 14.385 USD. Today NPCE is down by -1.47%. In the past month the price increased by 4.06%. In the past year, price increased by 40.12%.
NPCE Key Statistics
- Market Cap
- 484.343M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.66
- Dividend Yield
- N/A
NPCE Stock Performance
NPCE Stock Chart
NPCE Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to NPCE. When comparing the yearly performance of all stocks, NPCE turns out to be only a medium performer in the overall market: it outperformed 69.48% of all stocks.
NPCE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NPCE. NPCE may be in some trouble as it scores bad on both profitability and health.
NPCE Earnings
On March 3, 2026 NPCE reported an EPS of -0.08 and a revenue of 26.59M. The company beat EPS expectations (48.21% surprise) and beat revenue expectations (5.14% surprise).
NPCE Forecast & Estimates
14 analysts have analysed NPCE and the average price target is 20.27 USD. This implies a price increase of 40.93% is expected in the next year compared to the current price of 14.385.
For the next year, analysts expect an EPS growth of -16.79% and a revenue growth 0.25% for NPCE
NPCE Groups
Sector & Classification
NPCE Financial Highlights
Over the last trailing twelve months NPCE reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 30.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.33% | ||
| ROE | -112.79% | ||
| Debt/Equity | 3.09 |
NPCE Ownership
NPCE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.73 | 177.764B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.15 | 160.743B | ||
| SYK | STRYKER CORP | 21.9 | 127.168B | ||
| BSX | BOSTON SCIENTIFIC CORP | 17.52 | 92.877B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.87 | 47.155B | ||
| IDXX | IDEXX LABORATORIES INC | 38.84 | 45.976B | ||
| BDX | BECTON DICKINSON AND CO | 11.36 | 44.226B | ||
| RMD | RESMED INC | 18.26 | 32.768B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.47 | 32.085B | ||
| DXCM | DEXCOM INC | 24.96 | 24.327B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.78 | 17.804B | ||
| HOLX | HOLOGIC INC | 15.48 | 16.969B | ||
| PODD | INSULET CORP | 31.38 | 14.326B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NPCE
Company Profile
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Company Info
IPO: 2021-04-22
NEUROPACE INC
455 N. Bernardo Avenue
Mountain View CALIFORNIA US
CEO: Michael Favet
Employees: 209
Phone: 16502372700
NEUROPACE INC / NPCE FAQ
Can you describe the business of NEUROPACE INC?
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
What is the current price of NPCE stock?
The current stock price of NPCE is 14.385 USD. The price decreased by -1.47% in the last trading session.
Does NPCE stock pay dividends?
NPCE does not pay a dividend.
How is the ChartMill rating for NEUROPACE INC?
NPCE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about NEUROPACE INC (NPCE) stock?
14 analysts have analysed NPCE and the average price target is 20.27 USD. This implies a price increase of 40.93% is expected in the next year compared to the current price of 14.385.
Can you provide the growth outlook for NEUROPACE INC?
The Revenue of NEUROPACE INC (NPCE) is expected to grow by 0.25% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for NEUROPACE INC?
NEUROPACE INC (NPCE) has a market capitalization of 484.34M USD. This makes NPCE a Small Cap stock.